CoChat

Tolerance in Antidepressant Treatment

Baldessarini, Ross J., Ghaemi, S. Nassir, Viguera, Adele C. · 2002 · Psychotherapy and Psychosomatics

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Despite compelling evidence of rapid relapse into depression within 1–3 months after discontinuing long-term antidepressant treatment, and a strong relationship of this risk to prior illness history, the place for maintenance antidepressant treatment in recurrent major depression and other disorders remains uncertain [1, 2]. Most long-term therapeutic studies in major depression involve tricyclic antidepressants; they average 17 months in duration [1, 2]; only one small trial of imipramine reached 5 years [3]. The therapeutic model involved derives from evidence of protective effects of long-term lithium treatment in unipolar as well as bipolar major affective disorders [4, 5]. Evidence of long-term effectiveness and safety for antidepressant treatment in bipolar disorders is lacking [2, 6]. There is also growing evidence that a loss of benefit can emerge with long-term antidepressant treatment or on retreatment after discontinuation [7, 8, 9, 10], perhaps even more commonly among bipolar than unipolar depressed patients [11].In this issue, Schmidt et al. [12]and Fava et al. [13]provide relevant observations from their long-term collaborative study of outpatients with moderately severe, recurrent unipolar depression who relapsed during long-term treatment with (±)-fluoxetine. They extend previous observations that increasing fluoxetine doses from 20 to 40 mg/day can rescue some late failures [14], as did increasing the dose of enteric-coated fluoxetine tablets from 90 to 180 mg/week [12](table 1). Underlying mechanisms and implications of this phenomenon remain unclear, but invite comment.After responding to an open trial of fluoxetine at 20 mg/day, 31.4% (119/379) of depressives relapsed within an average of 107 days of blinded fluoxetine maintenance treatment, in which daily dosing was somewhat more effective than weekly (25.9 vs. 36.8% relapse rate; χ2 = 5.24, p = 0.022) [15]. Among 56 subjects relapsing at 20 mg/day, 57.1% responded to a blindly determined doubled dose of fluoxetine for another 6–24 weeks, as did 71.9% of 64 patients who relapsed on 90 mg/week of enteric-coated drug. Therefore, 35.0% (42/120) of patients relapsing during long-term fluoxetine treatment were not rescued by doubling the dose. These treatment-resistant subjects represent 11.0% (0.314 × 0.350) of all subjects starting long-term fluoxetine treatment.As expected, more patients relapsed during blinded maintenance with a placebo (61/122 = 50.0%) than with fluoxetine [119/379 = 31.4%; χ2 (1 d.f.) = 13.9, p = 0.0002], and with a shorter average latency (2.87 vs. 3.57 months) [12]. The larger relapse risk with placebo suggests that a loss of placebo response did not account for relapses during fluoxetine maintenance. Of those maintained on placebo after blinded withdrawal from 13 weeks of open treatment with fluoxetine, 62.3% (33/53) regained and maintained response to 20 mg/day on retreatment [13].Response during secondary trials of fluoxetine was unexpectedly greater than in primary trials [431/932 = 46.2% vs. 42/120 = 35.0% of subjects; χ2 (1 d.f.) = 5.43, p = 0.020]. This finding does not indicate any loss of response to retreatment. However, sampling may be biased by including all eligible subjects initially, but retreating only initially fluoxetine-responsive patients. Relative risk of unresponsiveness to retreatment with other antidepressants remains inadequately studied [7, 8, 9, 10, 11], but preliminary findings suggest variance among specific agents [11]. Similarly, responses to retreatment after failing lithium among bipolar disorder patients have been inconsistent [16, 17].It is reassuring that increasing the dose of fluoxetine led to sustained secondary responses in a majority (78/120 = 65.0%) of relapsed depressive patients, though only with limited follow-up (6–24 weeks) [12]. More concerning, however, is that 35% of patients relapsing during maintenance fluoxetine treatment did not respond to an increased dose, and that 11% of those started on long-term fluoxetine treatment became treatment resistant within only about 3.6 months of maintenance treatment [12, 15].Loss of previous antidepressant benefit over time, with incomplete return of response even after doubling the drug dose, are consistent with pharmacological tolerance. Underlying mechanisms are unknown, but induced metabolic clearance of antidepressants is readily tested with assays of blood drug concentrations over time. It also remains to be proved, as we suspect [11], that antidepressants vary in risk of therapeutic tolerance, and whether longer antidepressant treatment, or higher maintenance doses might further increase the risk of tolerance.That dosing may be significant is suggested by the finding [12]that response to increased dosing was nearly significantly greater among those maintained with the lesser dose of 90 mg/week (equivalent to 12.9 mg/day) vs. 20 mg/day of fluoxetine [respective secondary failure rates: 18/64 = 28.1% vs. 24/56 = 42.9%; χ2 (

Overview

Integrity signals

Registry

Crossref · 10.1159/000063641

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 16 references

Cited by

See all 42

Metadata

Authors
Baldessarini, R. J., Ghaemi, S. N., & Viguera, A. C.
Affiliations
Harvard University (US)
Venue
Psychotherapy and Psychosomatics
Publisher
S. Karger AG
Published
2002
Volume
71
Issue
4
Pages
177-179
ISSN
  • 0033-3190 (ISSN-L)
  • 1423-0348
OpenAlex
W1968373061
Cited by
42
References
16
Citations by year
2024: 4 · 2022: 1 · 2018: 1 · 2016: 1 · 2014: 1 · 2013: 1
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Psychotherapy and Psychosomatics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
antidepressant treatment, recurrent major depressive disorder, fluoxetine, dose escalation, tricyclic antidepressants, bipolar depression, lithium
MeSH terms
Major Depressive Disorder, Drug Administration Schedule, Drug Tolerance, Fluoxetine, Humans, Recurrence, Treatment Refusal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tolerance in Antidepressant Treatment. https://app.cochat.ai/papers/10.1159/000063641
The paper
Baldessarini, R. J., Ghaemi, S. N., & Viguera, A. C. (2002). Tolerance in Antidepressant Treatment. Psychotherapy and Psychosomatics. https://doi.org/10.1159/000063641

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.